Stay updated on Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T06:26:24.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of a new study on Triple Negative Breast Cancer, with AstraZeneca as a collaborator, and a revision update to v2.15.0. Key details about the study's objectives and eligibility criteria have been removed, which may impact the understanding of the study's scope.
    Difference
    42%
    Check dated 2025-04-16T20:37:24.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T14:56:27.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-02T00:20:54.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1.0%
    Check dated 2025-02-24T23:10:33.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1.0%
    Check dated 2025-02-10T16:53:53.000Z thumbnail image

Stay in the know with updates to Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.